Anzeige
Erschienen in:
18.09.2019 | Review
Prophylactic abdominal aortic balloon occlusion in patients with pernicious placenta previa during cesarean section: a systematic review and meta-analysis from randomized controlled trials
Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2019
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Pernicious placenta previa induces severe hemorrhage during cesarean section. Abdominal aorta balloon occlusion (AABO) is considered as an effective operation for patients with pernicious placenta previa. The aim of this study was to investigate the clinical application of abdominal aortic balloon occlusion in the placenta previa and cesarean section by systematic review and meta-analysis.
Methods
MEDLINE, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), WAN-FANG DATA and CQVIP were searched from inception to Jan. 15th, 2019. Operative time, intraoperative blood loss volume, postoperative hospitalization duration, intraoperative blood transfusion volume, hysterectomy rate, lower extremity thrombosis rate, ICU admission rate, adverse reaction rate, neonatal birth weight, Apgar 1-min and 5-min scores were regarded as the endpoints. Randomized controlled trials (RCT) were used for meta-analysis.
Results
Fourteen articles were retrieved from total 650 articles, and the results of meta-analysis showed that application of intraoperative AABO had the ability to reduce the operative time (WMD = − 16.581, 95% CI − 26.690 to − 6.472; P = 0.001), the intraoperative blood loss volume (WMD = − 1202.69, 95% CI − 1732.25 to − 673.12; P < 0.001), the intraoperative blood transfusion volume (WMD = − 1202.69, 95% CI − 1732.25 to − 673.12; P < 0.001). The hysterectomy rate (RR = 0.279, 95% CI 0.164–0.474; P < 0.001), postoperative hospitalization duration (WMD = − 1.423, 95% CI − 2.070 to − 0.776; P < 0.001) and the balloon preset time (WMD = − 13.793, 95% CI − 15.341 to − 12.244; P < 0.001; I2 = 0.0%) were also reduced in AABO group.
Conclusions
Application of AABO in patients with pernicious placenta previa is safe and effective, which is worthy of clinical promotion.